Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 oct. 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring Announces Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 with Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia Prevention

Plinabulin Significantly Reduced Grade 3/4 CIN and Bone Pain When Combined with Neulasta, Compared to Neulasta Monotherapy, in Breast Cancer Patients Receiving High-Risk TAC Chemotherapy Company to...
23 oct. 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Has the Potential to Positively Impact Tumor Microenvironment

Data Demonstrating Plinabulin’s Immune-Enhancing Potential Presented at European Society for Medical Oncology (ESMO) Congress NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:...
23 oct. 2018 07h00 HE | Source: BeyondSpring, Inc.

Beyondspring Provides Operational Update and Second-Quarter 2018 Financial Results

- Reported Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 Evaluating Plinabulin in Combination With Neulasta for Chemotherapy-Induced Neutropenia (CIN) Prevention - On Track to...
19 oct. 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring to Host Second-Quarter 2018 Financial Results and Operational Update Conference Call on October 23, 2018

Dr. Douglas Blayney from Stanford University to Join to Discuss Recently Announced Clinical Data NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global,...
16 oct. 2018 07h06 HE | Source: BeyondSpring, Inc.

BeyondSpring’s Lead Asset, Plinabulin, Prevents Docetaxel Chemo-Induced-Neutropenia (CIN) Due to a Mechanism of Action Differentiated from G-CSF

Evidence of Neutrophil Demargination and Bone Marrow Transit Time Reduction by Plinabulin Presented at Joint Meeting of the Society for Leukocyte Biology and International Endotoxin and Innate...
04 oct. 2018 07h30 HE | Source: BeyondSpring, Inc.

Study Opens of BeyondSpring’s Lead Asset, Plinabulin, and Nivolumab + Ipilimumab in Small-Cell Lung Cancer

Rutgers Trial Aims to Demonstrate Reduction in Immune-Related Adverse Events, While Adding to Anti-Cancer Immune Effects for Patients NEW YORK, Oct. 04, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc....
03 oct. 2018 06h56 HE | Source: BeyondSpring, Inc.

BeyondSpring to Present Clinical Trial Data at Three Upcoming Scientific Conferences

NEW YORK, Oct. 03, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced...
25 sept. 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring’s Lead Asset, Plinabulin, Continues to Demonstrate Clinical Superiority Versus Standard of Care for Neutropenia

Phase 2 Data Show Plinabulin Significantly Reduces Thrombocytopenia in Docetaxel-Treated Patients Compared to Standard of Care Data Presented at 2018 IASLC World Conference on Lung Cancer NEW YORK,...
19 sept. 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring Strengthens Intellectual Property Portfolio with Newly Granted U.S. Patent for Plinabulin

NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced...
06 sept. 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring’s Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Neulasta for Prevention of Thrombocytopenia Induced by Docetaxel in Phase 2 Trial

Data Provide Further Support for Plinabulin’s Superior Product Profile Clinical Data Will be Presented at 2018 IASLC 19th World Conference on Lung Cancer NEW YORK , Sept. 06, 2018 (GLOBE NEWSWIRE)...

Page précédente